Literature DB >> 18682418

Hepatic giant cells in hepatitis C virus (HCV) mono-infection and HCV/HIV co-infection.

S T L Micchelli1, D Thomas, J K Boitnott, M Torbenson.   

Abstract

BACKGROUND: The clinical and biological significance of syncytial giant cell change of hepatocytes in hepatitis C viral (HCV) infection is poorly understood. AIM: To investigate the clinical and histological correlates of giant cell transformation in the setting of HCV mono-infection and co-infection with HCV and HIV.
METHODS: The prevalence of hepatocyte giant cell transformation was determined and serological, biochemical and histological findings examined.
RESULTS: Among 856 liver biopsy specimens, 22 cases (2.6%) showed giant cell transformation, representing 18 individuals. The median serum ALT was 37 IU/l, AST 49 IU/l, and alkaline phosphatase 97 IU/l. Eleven cases had HCV RNA loads available, with a median HCV RNA of 5.52 log IU/ml. Twelve of 17 individuals with available test results were also HIV positive (71%), compared to 46% of controls (p = 0.08). Giant cell transformation was found exclusively in zone 3 hepatocytes; the accompanying histological findings were otherwise typical of chronic HCV. The hepatic giant cells typically had a cytoplasmic appearance that resembled smooth endoplasmic reticulum proliferation. Most cases had only mild inflammation and fibrosis, with a median modified hepatic activity index (MHAI) grade of 3/18 and a median MHAI stage of 1/6. Three individuals had follow-up biopsies; all continued to have giant cell change.
CONCLUSION: Giant cell transformation occurs most commonly in the setting of HCV/HIV co-infection, but can also be seen in chronic HCV infection alone. Histologically, giant cells were located in zone 3 hepatocytes, were persistent over time, and do not appear to be a marker of aggressive hepatitis.

Entities:  

Mesh:

Year:  2008        PMID: 18682418     DOI: 10.1136/jcp.2008.058560

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  7 in total

1.  Syncytial giant cell hepatitis in a patient with chronic lymphocytic leukemia.

Authors:  Neil Gupta; Basile Njei
Journal:  J Dig Dis       Date:  2015-11       Impact factor: 2.325

2.  Management of giant cell hepatitis associated with chronic lymphocytic leukemia - a case series and review of the literature.

Authors:  Joanna M Rhodes; Stephen J Schuster; Emma E Furth; Kaitlin Kennard; Sunita Dwivedy Nasta; Jakub Svoboda; David L Porter; Anthony R Mato
Journal:  Cancer Biol Ther       Date:  2019-05-15       Impact factor: 4.742

3.  Autoimmune post-infantile giant cell hepatitis: a case report and review of the literature.

Authors:  Yasi Xiao; Zu-Hua Gao; Marc Deschenes
Journal:  Can Liver J       Date:  2021-04-29

Review 4.  Virus-Mediated Cell-Cell Fusion.

Authors:  Héloïse Leroy; Mingyu Han; Marie Woottum; Lucie Bracq; Jérôme Bouchet; Maorong Xie; Serge Benichou
Journal:  Int J Mol Sci       Date:  2020-12-17       Impact factor: 5.923

5.  Postinfantile giant cell hepatitis: an etiological and prognostic perspective.

Authors:  Chhagan Bihari; Archana Rastogi; Shiv Kumar Sarin
Journal:  Hepat Res Treat       Date:  2013-03-11

6.  Postinfantile Giant Cell Hepatitis with Features of Acute Severe Autoimmune Hepatitis Probably Triggered by Diclofenac in a Patient with Primary Myelofibrosis.

Authors:  Pinelopi Arvaniti; Kalliopi Zachou; George K Koukoulis; George N Dalekos
Journal:  Case Reports Hepatol       Date:  2018-03-11

7.  Post-infantile giant cell hepatitis: A single center's experience over 25 years.

Authors:  Bassem Matta; Ricardo Cabello; Mordechai Rabinovitz; Marta Minervini; Shahid Malik
Journal:  World J Hepatol       Date:  2019-12-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.